These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33841341)

  • 21. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.
    Bassi N; Fonarow GC
    Curr Cardiol Rep; 2018 Sep; 20(11):112. PubMed ID: 30259198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
    Camilli M; Lombardi M; Chiabrando JG; Zito A; Del Buono MG; Vergallo R; Aspromonte N; Lombardo A; Montone RA; Niccoli G; Biondi-Zoccai G; Crea F; Minotti G
    Am J Ther; 2021 Nov; 29(2):e199-e204. PubMed ID: 35389572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 25. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis.
    Zou X; Shi Q; Vandvik PO; Guyatt G; Lang CC; Parpia S; Wang S; Agarwal A; Zhou Y; Zhu Y; Tian H; Zhu Z; Li S
    Ann Intern Med; 2022 Jun; 175(6):851-861. PubMed ID: 35404670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 27. Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium-glucose cotransporter 2 inhibitors? A correlation meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Diabetes Obes Metab; 2024 Jan; 26(1):392-395. PubMed ID: 37853835
    [No Abstract]   [Full Text] [Related]  

  • 28. Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
    Yamani N; Usman MS; Akhtar T; Fatima K; Asmi N; Khan MS
    Eur J Prev Cardiol; 2020 Apr; 27(6):667-670. PubMed ID: 30966822
    [No Abstract]   [Full Text] [Related]  

  • 29. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: A systematic review and meta-analysis of randomized controlled trials.
    Idowu A; Adebolu O; Wattanachayakul P; Obomanu E; Shah S; Lo KB; Pressman G
    Curr Probl Cardiol; 2024 Aug; 49(8):102648. PubMed ID: 38759767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
    Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
    McKenzie T; Hale GM; Miner A; Colón Colón J; Evins G; Wade J
    Heart Fail Rev; 2024 Mar; 29(2):549-558. PubMed ID: 38300379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials.
    Yin D; Qiu M; Wei X; Duan X
    Medicine (Baltimore); 2021 Jul; 100(28):e26561. PubMed ID: 34260534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.